Clinical characteristics and outcomes of Hodgkin Lymphoma: A single institution retrospective cohort study.

Authors

Anwar Rjoop, Rania Al-Samama'h, Taima Sari Al-Ullemat, Rahaf Alshamali, Batool El-Dwakat, Roaa Al-Saidi, Noor Abdalhakem, Saja Alsarhan, Asmaa Ajarmeh

Published in

PloS one. Volume 21. Issue 7. Pages e0353363. Epub Jul 10, 2026.

Abstract

Hodgkin lymphoma (HL) is a highly curable B-cell lymphoma, but a group of patients may experience resistance to initial treatment or progress to refractory disease. Moreover, they may experience relapses or long-term complications such as infertility and secondary neoplasms. In this retrospective cohort study, 257 patients diagnosed with HL between 2002 and 2022 were included to identify clinical and laboratory predictors of survival that may contribute to managing patient treatment and follow-up strategies. Demographic, clinical, treatment, and laboratory data at diagnosis were collected from patients' e-records. Overall survival (OS) and progression-free survival (PFS) were analyzed using Kaplan-Meier curves and log-rank tests. Univariable and multivariable Cox proportional hazards models were used to identify independent predictors of death. The median age at diagnosis was 29 years, with 54.9% males. Nodular sclerosis was the most common subtype (34.6%). Univariable Cox regression analysis showed that high creatinine levels (HR 7.55, 95% CI 2.62-21.81, p < .001), low platelet count (HR 4.87, 95% CI 1.58-14.94, p = .006), and high total bilirubin (HR 3.76, 95% CI 1.34-10.55, p = .012) are factors associated with poor survival. In the exploratory multivariable Cox regression analysis, poor response to treatment was strongly associated with poor survival (HR 7.89, 95% CI 2.39-26.06, p=<.001), followed by low platelet count (HR 4.72, 95% CI 1.28-17.46, p = 0.020). This may suggest that poor treatment response and low platelet count are independent predictors of poor survival in HL patients but require confirmation in a larger cohort. Early detection of high-risk patients based on these clinical and laboratory results may improve patient treatment and follow-up strategies.

PMID:
42430341
Bibliographic data and abstract were imported from PubMed on 11 Jul 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.